Global healthcare investment giant, OrbiMed, has successfully amassed more than $4.3 billion in commitments for its new private investment funds. Among these, OrbiMed Asia Partners V stands out, reflecting the firm’s strong foothold in the rapidly expanding Asian healthcare sector.
The firm’s latest funds, including Asia Partners V, will facilitate investments in innovative ventures across the healthcare landscape, from seed stage start-ups to growth capital opportunities. The funds target sectors ranging from biopharmaceuticals to technology-enabled healthcare services, underscoring OrbiMed’s comprehensive approach.
OrbiMed’s expansive team of over 130 professionals, with expertise spanning from incubation to finance, are stationed in pivotal healthcare markets, including key locations in Asia. This strategic positioning enables the firm to tap into the dynamic and diverse Asian healthcare ecosystem.
The new funds have garnered investments from a diverse pool, including medical institutions, sovereign wealth funds, and university endowments. Commenting on the achievement, Carter Neild, a Managing Partner of OrbiMed, expressed gratitude towards their enduring partners and affirmed OrbiMed’s commitment to living up to the high expectations set by them in the forthcoming years.